Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
GILD's first-quarter adjusted loss per share of $1.32 per share was narrower than the Zacks Consensus Estimate of a loss of $1.49. In the year-ago quarter, the company reported adjusted earnings of $1.37 per share. The year-over-year decrease was due to an acquired in-process research and development (IPR&D) charge of $3.9 billion, or $3.14 per share, related to the acquisition of CymaBay Therapeutics, Inc. Total revenues of $6.7 billion beat the Zacks Consensus Estimate of $6.4, primarily due to higher HIV, Oncology and Liver Disease sales. The stock is trading up in response to the results. Gilead's shares have lost 19.4% year to date compared with the industry's decline of 9.3%. Image Source: Zacks Investment Research Quarter in Detail Total product sales were up 5% to $6.6 billion. Excluding Veklury, product sales increased 6% to $6.1 billion. HIV product sales grew 4% year over year to $4.34 billion, driven by higher demand. The figure beat both the Zacks Consens
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024 [Yahoo! Finance]Yahoo! Finance
- Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024Business Wire
- 5 Biotech Stocks Worth Adding to Your Portfolio in 2024 [Yahoo! Finance]Yahoo! Finance
- RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 [Yahoo! Finance]Yahoo! Finance
- Forbes Has Listed Gilead as One of America's Best Employers for Diversity [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- GILD's page on the SEC website